Source comparison
Does BPC-157 Help Carpal Tunnel: Product & Treatment Comparison
Before considering any investigational peptide, understanding how it compares to existing evidence-based treatments clarifies realistic expectations. BPC-157 (investigational) Reduces inflammatory cytokines, promotes nerve revascularisation and Schwann cell pr
This comparison does not assign a generated winner or score.
- Before considering any investigational peptide, understanding how it compares to existing evidence-based treatments clarifies realistic expectations.
- BPC-157 (investigational)
- Reduces inflammatory cytokines, promotes nerve revascularisation and Schwann cell proliferation
- Preclinical only (rodent models)
- Unknown in humans
- No published human trials; optimal dosing, delivery route, and treatment duration unestablished
- Biological plausibility is high based on animal nerve injury models, but clinical translation remains unproven. Appropriate for research protocols only.
- Corticosteroid injection
- Suppresses inflammation via glucocorticoid receptor activation
- Moderate (RCTs in humans)
- 60–70% symptom relief at 6 weeks
- 50%+ recurrence within 12 months; does not promote nerve repair
- Gold-standard non-surgical intervention for mild-to-moderate cases. Temporary relief without addressing structural nerve damage.
- Wrist splinting (neutral position)
- Reduces intracarpal pressure by preventing wrist flexion/extension
- High (multiple RCTs)
- 50–60% improvement in mild cases
- Compliance-dependent; ineffective in moderate-to-severe cases
- First-line conservative treatment. Works by reducing mechanical compression but does not reverse existing nerve damage.
- Surgical carpal tunnel release
- Mechanically decompresses median nerve by dividing transverse carpal ligament
- High (extensive surgical outcome data)
- 85–95% good-to-excellent outcomes
- 5–10% persistent symptoms; scar sensitivity in ~15%
- Definitive treatment for moderate-to-severe cases or failed conservative management. Success rate highest when performed before irreversible nerve damage.
- Oral NSAIDs
- Reduces prostaglandin-mediated inflammation
- Low for carpal tunnel specifically
- Minimal sustained benefit
- Does not address nerve compression; GI/cardiovascular side effects with chronic use
- Not recommended as standalone treatment. May provide temporary symptom relief during activity modification.